Open Access Open Access  Restricted Access Subscription Access

Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity of Anti Hyper Lipidemic Drug Like Fluvastatin

Muralinath E., Madhavi Latha C., Ramadevi Ch., Srivalli A., Kavya Y., Vidya P. V., Sudheer K., Guruprasad M., Sony Sharlet E.

Abstract


In adults, fluvastatin is meant for hypercholesterolemia and mixed dyslipidemia to reduce the amount of total cholesterol in the blood. Particularly, this therapy decreases low-density lipoprotein cholesterol and triglycerides and enhances high-density lipoproteins. If combined along with a low-fat diet, a weight-loss program, and exercise, fluvastatin may decrease the risk of heart attack and stroke in people who have heart disease or are at risk of generating heart disease. This activity explains about the indications, dosing, contraindications, monitoring, and toxicity of fluvastatin and highlights the role of the interprofessional team in directing patient therapy to enhance outcomes for patients along with cardiovascular disease.

 


Full Text:

PDF

References


Lim, T. H., Orija, I. B., & Pearlman, B. L. (2014). The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: What clinicians need to know. Postgraduate Medicine, 126(7), 35–44.

Yuan, J. N., Tsai, M. Y., Hegland, J., & Hunninghake, D. B. (1991). Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis, 87(2–3), 147–157.

Hirota, T., & Ieiri, I. (2015). Drug-drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism & Toxicology, 11(9), 1435–1447.

Tse, F. L., Jaffe, J. M., & Troendle, A. (1992). Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. Journal of Clinical Pharmacology, 32(7), 630–638.

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd‐Jones, D. M., McBride, P., Schwartz, J. S., Shero, S. T., Smith, S. C., Watson, K., & Wilson, P. W. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25 Pt B), 2889–2934.

Peters, T. K., Mehra, M., & Muratti, E. N. (1993). Efficacy and safety of fluvastatin in hypertensive patients: An analysis of a clinical trial database. American Journal of Hypertension, 6(11 Pt 2), 340S–345S.

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005). Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: The PRIMO study. Cardiovascular Drugs and Therapy, 19(6), 403–414.

Mauricio, R., & Khera, A. (2022). Statin use in pregnancy: Is it time for a paradigm shift? Circulation, 145(7), 496–498.

National Institute of Child Health and Human Development. (2018). Fluvastatin. In Drugs and Lactation Database (LactMed®).

National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Fluvastatin. In LiverTox: Clinical and research information on drug-induced liver injury.

Abed, W., Abujbara, M., Batieha, A., & Ajlouni, K. (2022). Statin induced myopathy among patients attending the National Center for Diabetes, Endocrinology, & Genetics. Annals of Medicine and Surgery, 74, 103304.

Nazir, S., Lohani, S., Tachamo, N., Poudel, D., & Donato, A. (2017). Statin-associated autoimmune myopathy: A systematic review of 100 cases. Journal of Clinical Rheumatology, 23(3), 149–154.

Schwier, N. C., Cornelio, C. K., & Boylan, P. M. (2022). A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy, 42(4), 320–333.

Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 134(21), e468–e495.

Jokubaitis, L. A. (1994). Updated clinical safety experience with fluvastatin. American Journal of Cardiology, 73(14), 18D–24D.

Hagen, E., Istad, H., Ose, L., Bodd, E., Eriksen, H. M., Selvig, V., Bard, J. M., Fruchart, J. C., Borge, M., & Wolf, M. C. (1994). Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. European Journal of Clinical Pharmacology, 46(5), 445–449.

Olotu, B. S., Shepherd, M. D., Novak, S., Lawson, K. A., Wilson, J. P., Richards, K. M., & Rasu, R. S. (2016). Use of statins and the risk of incident diabetes: A retrospective cohort study. American Journal of Cardiovascular Drugs, 16(5), 377–390.

Patel, P. P., & Jackson, C. D. (2022). When statins get physical: A curious cause of statin myopathy. Southern Medical Journal, 115(4), 266–269.

Barry, A. R., Beach, J. E., & Pearson, G. J. (2018). Prevention and management of statin adverse effects: A practical approach for pharmacists. Canadian Pharmacists Journal, 151(3), 179–188.

Goff, D. C., Lloyd‐Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., Robinson, J. G., Schwartz, J. S., Shero, S. T., Smith, S. C., Sorlie, P., Stone, N. J., & Wilson, P. W. F. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25 Pt B), 2935–2959.

Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Kemper, A. R., Krist, A. H., Kurth, A. E., Landefeld, C. S., LeFevre, M. L., Mangione, C. M., Phillips, W. R., Owens, D. K., Phipps, M. G., & Pignone, M. P. (2016). Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA, 316(19), 1997–2007.


Refbacks

  • There are currently no refbacks.